Thank you you, all us. Pete, for joining and thank
of jump we candidates genetically relapsed/refractory AML. unmet from In menin-KMTXA protein-protein interaction highlighted once-daily ziftomenib American patients with AML profile ziftomenib drug to our of of of trial Hematology proud in for December, at Society ziftomenib is were in. the Phase X The and data patients Annual with safety the high our oral data updated encouraging defined treatment need. the ASH Meeting. at report targeting clinical Let’s right activity the
as in been to setting. date highest of median represents To XX% the on data treated this relapsed/refractory one the the a cutoff among patients reached ASH AML XX response the XX. A knowledge, had complete October at rate rates for recovery count dose. targeted milligram with duration reported data response of Notably, included with a therapies full XXX not NPMX-mutant of our response
once-daily activity, resulted strong recommended dosing In designation meeting of observed addition favorable schedule dose milligrams with which FDA. and a tolerability, clinical C XXX in profile Phase following and X Type ziftomenib encouraging a the as demonstrated to positive safety the
Phase interactions, or and registration-directed in FDA Building the AML. ziftomenib recently relapsed NPMX-mutant our momentum the of our patients on announced X dosed in Phase refractory X trial first data of we
expect enroll United the total States patients We and Europe. duration is transfusion CRh, XX primary independence, of secondary endpoint safety or a tolerability. to endpoints CR in and of The and key response, include
team. also trial represents interest which cases in targeted the yet speaks Dosing the testament menin patients unmet approximately our first need a of we’ve XX% marks disease of AML of our is and to NPMX-mutant exists. program and the significant the no in ziftomenib hard enrolling for accounts trial milestone to a registration-directed begun patients therapy with significant ziftomenib The and speed of our in work a new significant dedication for which investigators. among approved AML annually, for
FLTX AML risk mutations, outcomes Although, pretend risk NPMX-mutant IDH diagnosis, or other when are or X prognosis poor remains more to are favorable initial after chemotherapy, also may poor as and survival of particularly present. such untreated initial relapse X high upon the
IDH transplants our trial of all a FLTX patients had cutoff. of ziftomenib XX in at patient prior Notably, CR whom NPMX-mutant AML two-thirds for cell of minimal ziftomenib on failed milligrams and/or including co-mutations, data either disease, Phase and evidence An for treatment with co-mutations, NPMX-mutant the multiple with trial residual the X DNMTXA than also IDH XX no FLTX X CR had achieved entered who of XXX a October with inhibitors. additional following cycles who achieved prior and/or more stem as remains
NPMX-mutations, a is strategies. combination in patients as In we addition ziftomenib with to future believe well-positioned monotherapy activity impressive for
and interactions dosing QTc drug-induced competitive is no several adverse by with prolongation, care. conviction advantages including of drug-drug enable evidence convenient that daily supported no oral of standards should administration key Our predicted
in evaluate including is to NPMX-mutant diligently rearranged current initiate AML. KOMET-XXX and combination KMTXA and care lines populations, working team KOMET-XXX trials the to Our standards with across patient earlier of and ziftomenib multiple in
these safety, tolerability combination ziftomenib regimens azacitidine, studies the and and X as gilteritinib X+X. in to designed therapeutic We’ve assess of and Phase venetoclax such key activity with
Our prioritize FLTX to combinations approach potential greatest safely value, ziftomenib various primarily establish the is those represent that commonly and populations regimens, where and largest combined venetoclax containing and with foundation regimens. a can be commercial used then
up AML ziftomenib with co-mutations inhibitors NPMX-mutant the to potential combine believe other exhibit and in in safely relative has FLTX FLTXG to Notably, more we particular, patients effectively of also In half inhibitors development. to menin [ph].
rational We differentiation demonstrated population, will combination to IDH been azacitidine. of as also in development the has in approaches combination KMTXA-rearranged previously in help syndrome mitigate that inhibitors believe the with
very first combination excited half We acute XXXX. with leukemias. about ziftomenib of the KOMET-XXX potential We’re for the to value studies unlock of first the the studies these our patients for in further of initiating anticipate
and investments NDA conviction menin continue ziftomenib the potential have its well program, to combination in as we investment significant continue in best-in-class including as prioritize be And the We strong in preparedness, inhibitor. to to studies.
NPMX-mutant further as meeting our mid-XXXX. the presentation at We dataset year including mature on a of look a the X forward medical ziftomenib of progresses, from trial program Phase to AML more in and updates sharing
inhibitor turn let’s to our attention transferase farnesyl programs. our Now,
FTIs emergence as past prevent several indications. or of tumor development to to resistance combination of the of delay agents the in we’ve therapies targeted Over solid large certain years, pioneered classes
in carcinoma, data lung cancer. with preclinical a including FTIs renal as growing kinase in of inhibitors, PIX therapies, combination KRAS inhibitors, and of number cell in kinase well and inhibitors EGFR is targeted as alpha GXXC supportive Our tyrosine inhibitors
to and Last these FDA generation of investigational KO-XXXX Phase of transferase other application with tolerability in which properties targeted for with upon potency, clearance X tumors. and a monotherapy in FIT-XXX pharmacokinetic candidates. activity announce inhibitor tumors. new pleased the physicochemical solid we mind. designed applications improve was drug with in FDI KO-XXXX of in advanced next developed KO-XXXX earlier solid we’re antitumor advanced trial, drug farnesyl adult treatment combination were was dose-escalation to Our month, evaluate KO-XXXX therapies intend safety, calling We preliminary for patients to as a and of
of KO-XXXX for next FIT-XXX address tipifarnib we starting an marks the evaluate combination genetic patients. to for PIX we kinase larger quarter. and continue Clearance in forward to with look important inhibitor subsets to in Meanwhile, program, IND third step HNSCC this of alpelisib alpha the
durable induce with we October, study the Cancer of patient response first PIKXCA-dependent mutation trial, partial for of continued we XX can Therapeutics In our on cell carcinoma EORTC-NCI-AACR PIKXCA tonsil durable reported in a the Symposium. a at than with have XX clinical September Molecular a the III tipifarnib Targets alpelisib KURRENT-HN weeks that squamous the patient HNSCC more Notably, the and of response combination stage demonstration achieved and in a cutoff. has a data as and
toxicities adverse each Treatment-related no of drug manageable, events dose-limiting safety KURRENT-HN profiles are in are with to the and with consistent date. reported known
tipifarnib to its shareholders, for care with Our trial for discontinue and lung to now patients, ongoing with prioritize health providers programs active the highest osimertinib. to development create on team our and the in optimal close determining dose current of decided further recommended goal combination potential is a we’ve in value identifying with combination dose a focusing those biologically and effort mid-XXXX. an of efforts schedule Phase X In
a We on namely value, focus the cash maintaining with believe those highest ziftomenib development to potential KO-XXXX, programs taking position. this disciplined our while approach and enables strong enhance us
relationship expertise. Finally, investment the The of a from in were development strengthens in equity and between BMS us investment support with corporate our the insights Squibb announce quarter. we and pleased Bristol $XX provides organizations strategy, equity ongoing to key Myers million from fourth our
to work of patients. with We’re science have with to the BMS pleased the the team and deliver excited confidence them innovative to benefit potential to
for discussion call of our now over to With turn financial a that, Tom I’ll the results.
